Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis.

Natalizumab is associated with a reduction of basic CSF inflammatory measures supporting its strong anti-inflammatory properties. The IgM index at the baseline predicted future brain volume loss during the course of natalizumab treatment.